Nivolumab Global Buyers List: Complete Guide to International Purchasers & Market Insights
Nivolumab, marketed under the brand name Opdivo, is a pioneering PD-1 inhibitor immunotherapy that has transformed the treatment landscape for multiple cancer types. Since its FDA approval in 2014, nivolumab has become one of the most significant oncology drugs globally, with indications spanning melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, and more than 15 distinct oncology settings.
For pharmaceutical suppliers, manufacturers, and distributors seeking to navigate the global nivolumab market, understanding the buyer landscape is essential. This comprehensive guide presents the most current Nivolumab global buyers list, analyzes purchasing patterns across key regions, and provides strategic intelligence for engaging with international buyers.
The global nivolumab market demonstrates robust growth trajectories. Market estimates place the value at approximately $9.1 billion in 2025, with projections reaching $16.4 billion by 2032 at a compound annual growth rate of 8.80%. Another analysis indicates the market will grow from $1.92 billion in 2025 to $2.17 billion in 2026 at a CAGR of 12.9%. This remarkable expansion reflects increasing cancer prevalence, expanding therapeutic indications, and growing adoption of immunotherapy worldwide.
Major Nivolumab Manufacturers and Their Global Distribution Networks
Understanding the supply side is fundamental to comprehending the buyer landscape. The global nivolumab market is dominated by two primary manufacturers:
Bristol-Myers Squibb (BMS) – Headquartered in the United States, BMS is the primary global manufacturer and marketer of Opdivo (nivolumab). The company holds marketing rights across the United States, Europe, China, and numerous other territories.
Ono Pharmaceutical – Based in Osaka, Japan, Ono Pharmaceutical co-developed nivolumab through a research collaboration with Medarex (later acquired by BMS) that began in 2005. Ono holds exclusive marketing and distribution rights for nivolumab within Japan.
The development pathway of nivolumab (ONO-4538/BMS-936558/MDX-1106) emerged from this strategic collaboration, establishing a dual-manufacturer framework that continues to shape global supply chains.
Beyond the originator manufacturers, a growing ecosystem of biosimilar developers and contract manufacturers is emerging. Notable players include Dr. Reddy’s Laboratories, which ranks as the #1 Indian exporter of nivolumab, and other Indian pharmaceutical companies such as Corsantrum Technology and Vama Lifecare Private Limited. Russia’s Biocad has also received approval for Nivocad, a biosimilar to BMS’s Opdivo, which is included on the WHO Model List of Essential Medicines.
Comprehensive Nivolumab Global Buyers List
Based on verified Indian Customs (DGFT) trade data covering 2022–2026, the global nivolumab buyer network comprises 47 active importers across 13 countries, representing a total import value of $2.3 million across 144 shipments. The following represents the most comprehensive Nivolumab global buyers list currently available.
Top Nivolumab Buyers by Import Value
| Rank | Buyer Name | Country | Import Value | Market Share |
|---|---|---|---|---|
| 1 | ALMAC PHARMACEUTICAL SERVICES PTE LIMITED | Singapore | $1.1M | 46.0% |
| 2 | COREX LLC | Russia | $773.4K | 33.9% |
| 3 | AS PER INVOICE | Brazil | $72.9K | 3.2% |
| 4 | STATE TRADING ORGANIZATION PLC | Maldives | $32.3K | 1.4% |
| 5 | JAIR CARLOS DE ARAUJO | Brazil | $30.5K | 1.3% |
Source: Indian Customs (DGFT) data
The top five buyers collectively control 85.9% of total import value, reflecting a highly concentrated buyer landscape.
Complete Nivolumab Buyer Directory
Singapore
- ALMAC PHARMACEUTICAL SERVICES PTE LIMITED – The largest global buyer with a 46.0% market share, purchasing $1.1M worth of nivolumab
- BIORELIANCE TESTING SERVICES
Russia
- COREX LLC – Second-largest buyer globally at $773.4K (33.9% market share); also the largest buyer of Dr. Reddy’s Laboratories’ nivolumab exports at $300.0K
Brazil
- AS PER INVOICE – $72.9K in purchases
- JAIR CARLOS DE ARAUJO – $30.5K
- FRANCISCO EUDES DA SILVA – $11.8K
Maldives
- STATE TRADING ORGANIZATION PLC – Largest importer in Maldives with $27.0K in purchases
- INDIRA GANDHI MEMORIAL HOSPITAL – $12.0K
- Two additional buyers (Invoice Raised to Maldives and one other)
Seychelles
United Kingdom
United States
Netherlands
Germany
Additional Buyers (Unnamed in Public Data)
- Combined buyer network spans 13 named purchasing companies, including 8 additional buyers not individually specified in public records
Indian Buyers of Nivolumab (Importers)
India also imports nivolumab from various global suppliers:
From United Kingdom
- DR REDDY’S LABORATORIES LIMITED – $28.2K (66.6% share)
- MSN LABORATORIES PRIVATE LIMITED – $6.8K
- BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED – $3.8K
From Ireland
- LUPIN LIMITED – $4.4K
From Sweden
- INTAS PHARMACEUTICALS LIMITED – $155.6K
From China
- BIO RAD LABORATORIES
- INTAS PHARMACEUTICALS LIMITED – $611
- INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED – $214
Hospital and Healthcare Buyers
Beyond pharmaceutical distributors and trading companies, numerous hospitals and healthcare institutions directly procure nivolumab:
- Leeds Teaching Hospitals NHS Trust (United Kingdom)
- Belfast Health & Social Care Trust (United Kingdom) – Multiple procurement contracts for Opdivo (nivolumab) valued at up to £430,000
- Hospital Universitario Central de Asturias (Spain)
- Hospital Umum Sarawak (Malaysia)
- Tengku Ampuan Afzan Hospital, Kuantan (Malaysia)
- Hospital del Salvador (Chile)
- Galician Health Service (Spain) – Framework agreement for oncological immunotherapy drugs including nivolumab
Supplier Network: Who Supplies Nivolumab to Global Buyers?
Understanding the supplier landscape helps buyers identify potential partners and helps suppliers benchmark their position.
Top Nivolumab Exporters from India
| Rank | Exporter | Export Value | Market Share |
|---|---|---|---|
| 1 | DR. REDDY’S LABORATORIES LTD | $1.1M | 46.0% |
| 2 | CORSANTRUM TECHNOLOGY | $577.3K | 25.3% |
| 3 | VAMA LIFECARE PRIVATE LIMITED | $217.8K | 9.5% |
| 4 | MODERN DRUG HOUSE | $74.3K | 3.3% |
| 5 | SPECIALITY MEDICINES LIMITED | $72.9K | 3.2% |
| 6 | RBN MEDITECH PRIVATE LIMITED | $27.6K | 1.2% |
Source: Indian Customs (DGFT) data
The top two suppliers (Dr. Reddy’s and Corsantrum Technology) together account for 71.3% of all nivolumab exports from India. India exports nivolumab through 23 registered manufacturers serving 47 buyers across 13 countries.
Dr. Reddy’s Laboratories – Buyer Network
Dr. Reddy’s Laboratories, the #1 Indian exporter, ships nivolumab to 5 countries through 6 buyers:
- COREX LLC (Russia) – $300.0K – Largest buyer
- LABCORP EARLY DEVELOPMENT (United Kingdom) – $20.9K
- BIOPHARMASPEC INC (United States) – $525
- CHARLES RIVER LABORATORIES, INC. (United States) – $250
- CERGENTIS B.V. (Netherlands) – $30
- PROTAGENE GMBH (Germany) – $20
Nivolumab Market Dynamics and Growth Drivers
Market Size and Projections
The nivolumab market demonstrates exceptional growth potential:
| Metric | Value |
|---|---|
| 2025 Market Value | $9.1 Billion |
| 2026 Projected Value | $2.17 Billion |
| 2032 Projected Value | $16.4 Billion |
| CAGR (2026–2032) | 8.80% |
| Opdivo Sales (2025) | ~$4.1 Billion |
Note: The variation between market size figures reflects different methodologies and market scope definitions. The $9.1 billion figure represents the broader nivolumab market, while the $2.17 billion figure represents a more narrowly defined market segment.
Key Growth Drivers
Rising Cancer Incidence – Non-small cell lung cancer (NSCLC) remains a primary driver. An estimated 238,340 people were diagnosed with lung cancer in the United States, with NSCLC accounting for 81% of all cases.
Expanding Indications – Nivolumab is now approved across more than 15 oncology settings, including melanoma, NSCLC, renal cell carcinoma, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, MSI-H/dMMR metastatic colorectal cancer, hepatocellular carcinoma, and esophageal cancer.
Personalized Medicine Adoption – The increasing adoption of personalized medicine, with treatments tailored to individual genetic profiles, continues to drive nivolumab utilization.
New Formulations – In December 2024, the FDA approved Opdivo Qvantig, a subcutaneous formulation of nivolumab combined with hyaluronidase-nvhy, expanding administration options and patient convenience.
Biosimilar Entry – The emergence of nivolumab biosimilars (Biocad’s Nivocad in Russia, and candidates from R-Pharm and Dr. Reddy’s) is expanding market access and affordability. In 2025, nivolumab recorded sales of approximately $4.1 billion, underscoring the scale of market opportunity.
Regional Market Insights
North America – The largest regional market, driven by established healthcare infrastructure, favorable reimbursement policies, and high oncology treatment rates.
Asia-Pacific – The fastest-growing region, with expanding oncology infrastructure and increasing healthcare investment.
Europe – A mature market with significant procurement through public healthcare systems and framework agreements.
Emerging Markets – Countries like Brazil, Russia, India, China, and Southeast Asian nations demonstrate growing demand, reflected in the diverse buyer base identified in trade data.
How to Find and Engage Nivolumab Buyers
Trade Data Platforms
Several platforms provide verified import-export data for nivolumab:
- DGFT (Directorate General of Foreign Trade, India) – Official source for Indian customs data
- TransDataNexus – Comprehensive pharmaceutical trade intelligence
- 52wmb.com – Global trade database with buyer-supplier information
- Pharmatradz – Platform connecting suppliers with bulk manufacturers and buyers
Government Procurement Portals
Many nivolumab buyers are government healthcare institutions and public hospitals. Key procurement platforms include:
- Find a Tender (United Kingdom) – UK government procurement notices
- Contracts Finder (United Kingdom) – UK contract award information
- Boletín Oficial (Argentina) – Official government procurement notices
- MyProcurement (Malaysia) – Malaysian government procurement
- Contratación del Estado (Spain) – Spanish government procurement
- Tenders On Time – International tender aggregation
Key Buyer Categories
- Pharmaceutical Distributors – Companies like ALMAC Pharmaceutical Services and COREX LLC that distribute to healthcare providers
- Government Procurement Agencies – State Trading Organization PLC (Maldives) and similar entities
- Hospital Groups – NHS Trusts, public hospital systems, and large healthcare networks
- Clinical Research Organizations – Companies like Labcorp Early Development and Charles River Laboratories purchasing for research purposes
- Biosimilar Developers – Pharmaceutical companies sourcing nivolumab for reference product testing and biosimilar development
Regulatory Considerations
Buyers and suppliers must navigate complex regulatory frameworks:
- USFDA – U.S. Food and Drug Administration approval required for U.S. market
- EMA – European Medicines Agency authorization for EU markets
- WHO-GMP – World Health Organization Good Manufacturing Practice certification
- DSCSA – Drug Supply Chain Security Act compliance for U.S. supply chain traceability
Suppliers listed on platforms like PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA, and TGA.
Strategic Recommendations for Suppliers
For Manufacturers and Exporters
Leverage Trade Data – Utilize verified customs data to identify active buyers in target markets and understand competitor positioning.
Target High-Concentration Markets – The top five buyers control 85.9% of import value. Strategic partnerships with these major buyers offer significant volume potential.
Expand Beyond India – While India is a major supplier, consider partnerships with originator manufacturers (BMS, Ono) and emerging biosimilar producers for comprehensive market coverage.
Pursue Regulatory Approvals – Obtain necessary certifications (WHO-GMP, USFDA, EU-GMP) to qualify for procurement from regulated markets.
Monitor Tender Opportunities – Regularly review government procurement portals for hospital and healthcare system tenders.
For Buyers and Procurement Professionals
Verify Supplier Credentials – Ensure suppliers hold appropriate manufacturing and export licenses.
Leverage Framework Agreements – Many healthcare systems offer framework agreements that streamline procurement.
Consider Biosimilar Options – With biosimilars entering the market, evaluate cost-effective alternatives while ensuring therapeutic equivalence.
Build Direct Relationships – Establish direct relationships with manufacturers to secure supply chain reliability and competitive pricing.
PAREXEL INTERNATIONAL MEXICO SA DE CV
BRISTOL MYERS SQUIBB DE MEXICO S DE RL DE CV
BRISTOL MYERS SQUIBB INDIA PRIVATE LIMITED
BỆNH VIỆN K
BIO RAD LABORATORIES INDIA PRIVATE LIMITED
BRISTOL MYERS SQUIBB PERU S A
BRISTOL MYERS SQUIBB DE CHILE
IMPERIAL MANAGED SOLUTIONS EAST AFRICA LIMITED
101 SUPPLY CHAIN SOLUTIONS INC
PAREXEL CLINICAL RESEARCH
BRISTOL MYERS SQUIBB DE COL S A
GENERICS AFRICA LIMITED
INTAS PHARMACEUTICALS LIMITED
QUINTILES CHILE
PAREXEL CLINICAL RESEARCH PHILIPPI
IMPERIAL LIFE SCIENCES PRIVATE LIMITED
ONCO PHARMA PRIVATE LIMITED
PAREXEL INTERNATIONAL
BI BIOTECH INDIA PRIVATE LIMITED
QUINTILES COLOMBIA LTDA
MSN LABORATORIES PRIVATE LIMITED
CÔNG TY CỔ PHẦN XUẤT NHẬP KHẨU Y TẾ THÁI AN
INCEPTA PHARMACEUTICALS LIMITED
ТОВАРИСТВО З ОБМЕЖЕНОЮ ВІДПОВІДАЛЬНІСТЮ ПІПІДІ ЮКРЕЙН 03038 М КИЇВ ВУЛ МИКОЛИ ГРІНЧЕНКА БУД 2 1 ПОВЕРХ 2
BEACON PHARMACEUTICALS PLC
ONCO PHARMA PVT LTD
ZISKA PHARMACEUTICALSLIMITED
CÔNG TY TNHH DƯỢC PHẨM HELIOS
ESKAYEF PHARMACEUTICALS LIMITED
EVEREST PHARMACEUTICALS LIMITED
NULIFE CONSULTANTS AND DISTRIBUTORS PRIVATE LIMITE
PERSONS INSTITUTIONS HOSPITALS IMPORTING OR EXPO
PHARMACIL LIMITED
ALLIANZ BIOINNOVATION
BIOMEDICAL LIFE SCIENCES
EPIRUS GLOBAL BUSINESS SOLUTIONS
RPS RESEARCH SERVICIOS S DE RL DE CV
SAI LIFE SCIENCES LIMITED
BIOCON BIOLOGICS LIMITED
DRUG INTERNATIONAL LIMITED
JOINT CLINICAL RESEARCH CENTRE LIMITED
MR SHAHID IQBAL
ROCHE MUSTAHZARLARI SANAYI ANONIM SIRKETI
RPS PERU S A C
SHILPA BIOLOGICALS PRIVATE LIMITED
VEEDA CLINICAL RESEARCH LIMITED
ТОВ ПАРЕКСЕЛ УКРАЇНА 03124 М КИЇВ БУЛ ВАЦЛАВА ГАВЕЛА БУД 6 КОРП 3 ЛІТЕРА У УКРАЇНА
HEALTHCARE PHARMACEUTICALS LTD
IQVIA TIBBI ISTATISTIK TICARET VE MUSAVIRLIK LIMITED SIRKETI
KRISHGEN BIOSYSTEMS PRIVATE LIMITED
M S ROTEX PHARMA PVT LIMITED
MR ABDUL AZIZ
MR ABDUL SATTAR ARIF
ONCOVANZ PHARMACEUTICALS PRIVATE LIMITED
OXIMIO LOJISTIK VE AMBALAJ SANAYI VE TICARET LIMITED SIRKETI
PAREXEL CLINICAL RESEARCH PHILIPPINES LTD CORP
PHARMADN SA
SMO TU LOJISTIK VE AMBALAJ SANAYI VE TICARET LIMITED SIRKETI
SULE MENE SAGLIK ARASTIRMA EGITIM DANISMANLIK BILISIM SANAYI TICARET ANONIM SIRKETI
SYED NAVEED UL HASSAN GILLANI
TAQWA PHARMACEUTICAL SURGICAL
WORLDWIDE CLINICAL RESEARCH S DE RL DE CV
ADVANCED CHEMICAL INDUSTRIES LTD
ARISTOPHARMA LTD CHANGE FROM
BRISTOL MYERS SQUIBB ARGENTINA SOCIEDAD DE RESPONSABILIDAD L
COMERCIAL FARMACEUTICA LEISA SOCIEDAD ANONIMA
CORPORACION IMPA DOEL S A
DINESH PRASAD SINHA
DR REDDY S LABORATORIES LTD
EVERON LIFE SCIENCES
GLOBE BIOTECH LIMITED
GLOBEL MARKETING SERVICES
ILKO ILAC SANAYI VE TICARET ANONIM SIRKETI
INTERLAB LABORATUAR URUNLERI SANAYI VE TICARET ANONIM SIRKETI
INVITROGEN BIOSERVICES INDIA PRIVATE LIMITED
KASHIV BIOSCIENCES PRIVATE LIMITED
LABEX CORPORATION
MOHAMMAD ISMAIL SHAIKH
MR MUSTAFA KAIZAR ADAM ALI
MR NAVEED UL HASSAN
MR RIZWAN HAMAYUN
MS SHAHNAZ GHULAM NABI
NO DISPONIBLE
NULIFE CONSULTANTS AND DISTRIBUTORS PRIVATE LIMITED
ONCO PHARMA PVT LTDC O ATIQ UR R
PAREXEL INTERNATIONAL TURKEY TIBBI DANISMANLIK SANAYI VE TICARET ANONIM SIRKETI
PHARMA MART LIMITED
PILL PACK HEATHCARE LIMITED
POPULAR PHARMACEUTICALS PLC
PPD INTERNATIONAL HOLDINGS INC
PRODUCTOS ROCHE SA DE CV
QAZI M RAZA
SHAUKAT KHANUM MEMORIAL TRUST
SIGMA ALDRICH CHEMICALS PRIVATE LIMITED
SYNGENE INTERNATIONAL LIMITED
SYNGENE SCIENTIFIC SOLUTIONS LIMITED
TARIQ MEHMOOD
THE ACME LABORATORIES LIMITED
UGANDA CANCER INSTITUTE
ZYDUS LIFESCIENCES LIMITED
ТОВ АРЕНСІЯ ЕКСПЛОРАТОРІ МЕДІСІН УКРАЇНА 08112 КИЇВСЬКА ОБЛ КИЄВО СВЯТОШИНСЬКИЙ Р Н СЕЛО КАПІТАНІВ
ТОВ НВП ЄНАМІН УКРАЇНА М КИЇВ 02094 ВУЛ ВІНСТОНА ЧЕРЧИЛЛЯ 78
ТОВАРИСТВО З ОБМЕЖЕНОЮ ВІДПОВІДАЛЬНІСТЮ ПІПІДІ ЮКРЕЙН 03038 М КИЇВ ВУЛ МИКOЛИ ГРІНЧЕНКА БУД 2 1 ПOВЕРХ 2
Conclusion
The global nivolumab market presents substantial opportunities for pharmaceutical suppliers, distributors, and buyers alike. The comprehensive Nivolumab global buyers list presented in this guide—featuring 47 active importers across 13 countries—provides a foundation for strategic market engagement.
With market values projected to reach $16.4 billion by 2032 and continuing expansion driven by rising cancer incidence, new indications, and innovative formulations, nivolumab remains one of the most significant oncology products in the global pharmaceutical landscape.
For suppliers, success depends on understanding the concentrated buyer landscape, securing appropriate regulatory approvals, and leveraging trade intelligence to identify and engage key purchasing entities. For buyers, navigating the supplier network—from originator manufacturers like Bristol-Myers Squibb and Ono Pharmaceutical to Indian exporters like Dr. Reddy’s Laboratories—requires careful due diligence and strategic procurement practices.
As the market evolves with biosimilar entry and expanding global access, the Nivolumab global buyers list will continue to grow and diversify, creating new opportunities across the pharmaceutical value chain.
